

Australian Medical Countermeasure Products Initiative

under the Next Generation Technology Fund (NGTF)

Nine NGTF topic areas

- DST Group led programs to drive development of game-changing military capabilities
- ***Leverage collaboration with industry, academia & Defence***
- Position Australian Defence to rapidly respond using new technologies

Groundwork for MCM

- Several years of campaigning for MCM to be included in NGTF
- Significant background work completed during 2012 National Capability Audit
- ***Initial funding for collaborative MCM product incubator.***

MCM Products

- Focused on MCM product development by improving translational research.
- ***Approximately \$40M allocated from the NGTF: requirement to be leveraged to over \$100M***
- Leveraged funds can be derived from cash or in-kind

NGTF: \$730M | MCM Products: >\$100M (\$40M NGTF)

Contact: Craig Rayner – d3 Medicine, A Certara Company on behalf of DST Group